Back to Search
Start Over
Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries.
- Source :
-
Research in social & administrative pharmacy : RSAP [Res Social Adm Pharm] 2021 Jun; Vol. 17 (6), pp. 1119-1139. Date of Electronic Publication: 2020 Sep 02. - Publication Year :
- 2021
-
Abstract
- Objectives: Tamsulosin is the most widely used alpha-1 blocker medication for managing benign prostatic hyperplasia (BPH) as indicated in the current practice guideline. The aim of this study was to compare all-cause medical costs and BPH-specific medical costs in older male adults with BPH treated with tamsulosin vs other alpha-1 blockers (i.e., doxazosin, terazosin, and alfuzosin).<br />Methods: This was a retrospective propensity-score matched cohort study based on 2006-2012 Medicare claims data. All-cause medical costs and BPH-specific medical costs were compared between tamsulosin and other alpha-1 blockers treatment groups using baseline-adjusted quantile regression analyses. The comparisons were performed at different percentiles of the cost distributions.<br />Results: 176,793 older male adults with BPH who used alpha-1 blockers were included in the analysis. All-cause medical costs in 75th and 95th percentiles of the cost distribution are substantially higher in tamsulosin treatment group when compared to other alpha-1 blocker medications (p < 0.05 for all). Tamsulosin treatment group had substantially higher BPH-specific medical costs in 99th percentile of the cost distribution when compared to doxazosin and terazosin (p < 0.001 for all). Overall, the top 5% of the patients with the highest all-cause medical costs accounted for approximately 45% of the overall all-cause medical costs, and the top 1% of the patients with the highest BPH-specific medical costs accounted for 39-51% of those costs.<br />Conclusion: Older adults with BPH who encountered higher medical expenses had substantially higher medical costs when treated with tamsulosin than other common alpha blockers. Cost-related quality of measures should be assessed to improve health outcomes in older adults with BPH.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1934-8150
- Volume :
- 17
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Research in social & administrative pharmacy : RSAP
- Publication Type :
- Academic Journal
- Accession number :
- 32891534
- Full Text :
- https://doi.org/10.1016/j.sapharm.2020.08.012